Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 130 participants.
Also called NCT05032651
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose health services research
- Phase
- Not applicable
- Enrolled
- 130 participants
- Registry
-
NCT05032651
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Taiwan
- Registry status
- Unknown status
Technical summary
Registry record NCT05032651. Randomized; double masking; primary purpose health services research. Start 2021-03-19 (actual); primary completion 2023-12-23 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients
- Acronym
- AI
- Condition
- End Stage Renal Disease on Dialysis
- Intervention (Device)
- novel artificial intelligence assisted platform
- Lead sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Collaborator
- National Sun Yat-sen University
Record details
- Record id
cardio:ct-nct05032651- Content hash
18e3665391db8f8c9f58bab6c97ad7895da273fb968090598a617843d4e6376b